Join the MS Community and Raise Awareness for MS this May

2 years ago

MS Society invites Canadians to participate in nationwide MS Awareness Month activities TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- For…

Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease

2 years ago

DALLAS, May 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class…

Mersana Therapeutics to Host First Quarter 2022 Conference Call on May 9, 2022

2 years ago

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering…

Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET

2 years ago

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives…

Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

2 years ago

SAN DIEGO, Calif., and SUZHOU, China, May 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global…

GuideWell and Highmark Ventures Lead $35 Million Funding Round in Kidney Health Leader Healthmap Solutions

2 years ago

Investment from Prominent Blues Health Plans Spotlights Growing Public Health ImperativeTAMPA, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- GuideWell and…

Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting

2 years ago

-- New data show setmelanotide treatment led to clinically meaningful improvements in lipid parameters, without affecting blood pressure or heart…

REPEAT – 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

2 years ago

The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in…

Motus GI Announces Upcoming Presentation of Topline Data from the EU Study of the Pure-Vu System at Digestive Disease Week 2022

2 years ago

FORT LAUDERDALE, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"),…

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Seventh Consecutive Year

2 years ago

MISSISSAUGA, Ontario, May 02, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for…